for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eli Lilly And Co

LLY.N

Latest Trade

243.20USD

Change

0.07(+0.03%)

Volume

333,963

Today's Range

242.38

 - 

247.75

52 Week Range

178.60

 - 

283.80

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications

Jan 6 (Reuters) - Eli Lilly and Co <LLY.N>::LILLY AND ENTOS PHARMACEUTICALS ENTER INTO RESEARCH AND COLLABORATION AGREEMENT TO SUPPORT THE DEVELOPMENT OF INNOVATIVE THERAPIES IN MULTIPLE NEUROLOGIC INDICATIONS.ELI LILLY - WILL BE RESPONSIBLE FOR SELECTING PLVS FOR CLINICAL DEVELOPMENT AND COMMERCIALIZATION.ELI LILLY - ENTOS WILL RECEIVE AN INITIAL PAYMENT OF $50 MILLION, WHICH INCLUDES AN EQUITY INVESTMENT BY LILLY.ELI LILLY - ENTOS IS ALSO ELIGIBLE TO RECEIVE UP TO $400 MILLION IN POTENTIAL MILESTONE PAYMENTS, AS WELL AS ROYALTIES.ELI LILLY - NO CHANGE TO LILLY'S 2021 OR 2022 NON-GAAP EARNINGS PER SHARE GUIDANCE AS A RESULT OF TRANSACTION.ELI LILLY - HAS ACQUIRED EXCLUSIVE RIGHTS TO ENTOS PHARMACEUTICALS' FUSOGENIX NUCLEIC ACID DELIVERY TECHNOLOGY.

ASPR Pauses Allocation Of Bamlanivimab And Etesevimab Together, Etesevimab Alone, And Regen-Cov

Dec 23 (Reuters) - FDA: :ASPR PAUSES ALLOCATION OF BAMLANIVIMAB AND ETESEVIMAB TOGETHER, ETESEVIMAB ALONE, AND REGEN-COV.DATA SHOW THAT IT IS UNLIKELY THAT BAMLANIVIMAB AND ETESEVIMAB ADMINISTERED TOGETHER OR REGEN-COV WILL RETAIN ACTIVITY AGAINST OMICRON VARIANT.BASED ON SIMILAR CELL CULTURE DATA CURRENTLY AVAILABLE, SOTROVIMAB APPEARS TO RETAIN ACTIVITY AGAINST THE OMICRON VARIANT.AN ADDITIONAL 300,000 DOSES OF SOTROVIMAB WILL BE AVAILABLE FOR DISTRIBUTION IN JANUARY.SHIPMENTS OF SOTROVIMAB DID RESUME THIS WEEK, AND DELIVERY OF 55,000 DOSES OF PRODUCT HAS BEGUN.Further company coverage: LLY.N. ((Reuters.Briefs@thomsonreuters.com;)).

Lilly's Lebrikizumab Demonstrated Significant Skin Improvement And Itch Relief When Combined With Topical Corticosteroids In People With Atopic Dermatitis In Third Phase 3 Study

Dec 21 (Reuters) - Eli Lilly and Co <LLY.N>::LILLY'S LEBRIKIZUMAB DEMONSTRATED SIGNIFICANT SKIN IMPROVEMENT AND ITCH RELIEF WHEN COMBINED WITH TOPICAL CORTICOSTEROIDS IN PEOPLE WITH ATOPIC DERMATITIS IN THIRD PHASE 3 STUDY.STUDY MET ALL PRIMARY AND KEY SECONDARY ENDPOINTS.SAFETY PROFILE CONSISTENT WITH PRIOR LEBRIKIZUMAB STUDIES IN ATOPIC DERMATITIS.GLOBAL REGULATORY SUBMISSIONS TO OCCUR NEXT YEAR BASED ON DATA FROM PHASE 3 CLINICAL TRIAL PROGRAM.AFTER COMPLETION OF ADVOCATE 1 AND ADVOCATE 2 TRIALS, CO AND ALMIRALL INTEND TO BEGIN U.S., EU AND OTHER REGULATORY SUBMISSIONS NEXT YEAR.

Lilly Highlights Innovation-Based Growth Strategy And Pipeline Developments Announces 2022 Financial Guidance

Dec 15 (Reuters) - Eli Lilly and Co <LLY.N>::LILLY HIGHLIGHTS INNOVATION-BASED GROWTH STRATEGY AND PIPELINE DEVELOPMENTS; ANNOUNCES 2022 FINANCIAL GUIDANCE AT INVESTMENT COMMUNITY MEETING.ELI LILLY - EXPECTS 2022 REVENUE TO BE BETWEEN $27.8 BILLION AND $28.3 BILLION.ELI LILLY - SEES 2021 EPS TO BE IN RANGE OF $6.18 TO $6.23 ON A REPORTED BASIS AND $8.15 TO $8.20 ON A NON-GAAP BASIS.ELI LILLY - EXPECTS 2022 OPERATING MARGIN TO BE ABOUT 30 PERCENT ON A REPORTED BASIS AND ABOUT 32 PERCENT ON A NON-GAAP BASIS.ELI LILLY - EXPECTS 2022 EARNINGS PER SHARE TO BE IN RANGE OF $8.00 TO $8.15 ON A REPORTED BASIS AND $8.50 TO $8.65 ON A NON-GAAP BASIS.ELI LILLY - NOW EXPECTS 2021 REVENUE TO BE BETWEEN $28.0 BILLION AND $28.3 BILLION.ELI LILLY- ON TRACK TO MEET ITS GOAL OF LAUNCHING 20 NEW MEDICINES OVER 10-YEAR PERIOD FROM 2014 TO 2023.ELI LILLY - CO'S NOVEL WEEKLY INSULIN IS ON TRACK TO PROGRESS TO PHASE 3 STUDIES IN 2022.FY2021 EARNINGS PER SHARE VIEW $8.02, REVENUE VIEW $27.63 BILLION -- REFINITIV IBES DATA.FY2022 EARNINGS PER SHARE VIEW $8.18, REVENUE VIEW $27.78 BILLION -- REFINITIV IBES DATA.ELI LILLY - PLANS TO INITIATE ADDITIONAL TIRZEPATIDE STUDIES THAT INCLUDE PHASE 3 STUDIES IN OBESITY RELATED OUTCOMES & OBSTRUCTIVE SLEEP APNEA.ELI LILLY- PLANS TO INITIATE PHASE 2 MECHANISM OF ACTION STUDY IN KIDNEY DISEASE.ELI LILLY- INITIATED A ROLLING SUBMISSION TO FDA FOR PIRTOBRUTINIB.ELI LILLY- INTENDS TO INITIATE A PHASE 3 STUDY TO EVALUATE EARLIER TREATMENT OF PROSTATE CANCER IN MID-2022.

Lilly Says Mirikizumab Demonstrates Superiority Over Placebo In Phase 3 Maintenance Study In Ulcerative Colitis

Dec 14 (Reuters) - Eli Lilly and Co <LLY.N>::MIRIKIZUMAB DEMONSTRATES SUPERIORITY OVER PLACEBO IN PHASE 3 MAINTENANCE STUDY IN ULCERATIVE COLITIS, SUPPORTING REGULATORY SUBMISSIONS IN 2022.ELI LILLY - SIGNIFICANTLY MORE PATIENTS TREATED WITH MIRIKIZUMAB MAINTENANCE DOSING ACHIEVED PRIMARY ENDPOINT OF CLINICAL REMISSION AT ONE YEAR (52 WEEKS).ELI LILLY - ALL KEY SECONDARY ENDPOINTS WERE MET.ELI LILLY - PLANS TO SUBMIT BLA TO FDA FOR MIRIKIZUMAB IN UC, FOLLOWED BY SUBMISSIONS TO OTHER REGULATORY AGENCIES AROUND WORLD IN FIRST HALF OF 2022.

Lilly And Foghorn Announce Strategic Collaboration For Novel Oncology Targets

Dec 13 (Reuters) - Foghorn Therapeutics Inc. <FHTX.O>::LILLY AND FOGHORN ANNOUNCE STRATEGIC COLLABORATION FOR NOVEL ONCOLOGY TARGETS USING FOGHORN’S PROPRIETARY GENE TRAFFIC CONTROL® PLATFORM.FOGHORN THERAPEUTICS INC. - COLLABORATION INCLUDES THREE ADDITIONAL DISCOVERY PROGRAMS.FOGHORN THERAPEUTICS - TO RECEIVE $300 MILLION UPFRONT AND AN EQUITY INVESTMENT BY LILLY OF $80 MILLION AT $20 PER SHARE.FOGHORN THERAPEUTICS - FOR BRM-SELECTIVE PROGRAM AND ADDITIONAL UNDISCLOSED TARGET PROGRAM, FOGHORN WILL LEAD DISCOVERY AND EARLY RESEARCH ACTIVITIES.FOGHORN THERAPEUTICS INC. - MAY RECEIVE UP TO A TOTAL OF $1.3 BILLION IN POTENTIAL DEVELOPMENT AND COMMERCIALIZATION MILESTONES.FOGHORN THERAPEUTICS INC. - FOGHORN AND LILLY WILL SHARE 50/50 IN U.S. ECONOMICS.FOGHORN THERAPEUTICS - ELIGIBLE TO RECEIVE ROYALTIES ON EX-U.S. SALES STARTING IN LOW DOUBLE-DIGIT RANGE & ESCALATING INTO TWENTIES BASED ON REVENUE LEVELS.FOGHORN THERAPEUTICS INC. - THERE WILL BE NO CHANGE TO LILLY'S 2021 NON-GAAP EARNINGS PER SHARE GUIDANCE AS A RESULT OF TRANSACTION.

Lilly And Regor Therapeutics Group Enter Into Strategic Collaboration To Discover And Develop Novel Therapies For Metabolic Disorders

Dec 10 (Reuters) - Eli Lilly and Co <LLY.N>::LILLY AND REGOR THERAPEUTICS GROUP ENTER INTO STRATEGIC COLLABORATION TO DISCOVER AND DEVELOP NOVEL THERAPIES FOR METABOLIC DISORDERS.ELI LILLY - LILLY WILL HAVE A LICENSE TO SELECT REGOR INTELLECTUAL PROPERTY WITH AN OPTION TO EXTEND LICENSE.ELI LILLY - LILLY WILL BE RESPONSIBLE FOR CLINICAL DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION WORLDWIDE.ELI LILLY - COMPANY IS ALSO ELIGIBLE TO RECEIVE UP TO $1.5 BILLION IN POTENTIAL PAYMENTS BASED ON ACHIEVEMENT OF PRESPECIFIED PRECLINICAL.ELI LILLY - REGOR WILL RECEIVE AN UPFRONT PAYMENT OF UP TO $50 MILLION, WHICH PARTIALLY INCLUDES AN EQUITY INVESTMENT BY LILLY IN REGOR.ELI LILLY - THERE WILL BE NO CHANGE TO LILLY'S 2021 NON-GAAP EARNINGS PER SHARE GUIDANCE AS A RESULT OF THIS TRANSACTION.ELI LILLY - REGOR WILL RECEIVE AN UPFRONT PAYMENT OF UP TO $50 MILLION.ELI LILLY - ELIGIBLE TO RECEIVE UP TO $1.5 BILLION IN POTENTIAL PAYMENTS BASED ON ACHIEVEMENT OF MILESTONES.

FDA Expands Authorization Of Two Monoclonal Antibodies For Treatment Of Covid-19 To Younger Pediatric Patients, Including Newborns

Dec 3 (Reuters) - FDA: :FDA EXPANDS AUTHORIZATION OF TWO MONOCLONAL ANTIBODIES FOR TREATMENT AND POST-EXPOSURE PREVENTION OF COVID-19 TO YOUNGER PEDIATRIC PATIENTS, INCLUDING NEWBORNS.FDA SAYS EUA FOR BAMLANIVIMAB AND ETESEVIMAB WAS ISSUED TO ELI LILLY AND CO.FDA - REVISED EUA OF BAMLANIVIMAB & ETESEVIMAB TO AUTHORIZE THEM TOGETHER FOR TREATMENT OF COVID-19 IN YOUNGER PEDIATRIC PATIENTS, INCLUDING NEWBORNS.FDA SAYS CHILDREN UNDER ONE YEAR OF AGE WHO ARE EXPOSED TO VIRUS THAT CAUSES COVID-19 MAY BE AT PARTICULARLY HIGH RISK FOR SEVERE COVID-19.FDA - ALSO AUTHORIZES BAMLANIVIMAB & ETESEVIMAB FOR POST-EXPOSURE PROPHYLAXIS FOR PREVENTION OF COVID-19 IN ALL PEDIATRIC PATIENTS, INCLUDING NEWBORNS. ((Reuters.Briefs@thomsonreuters.com;)).

Innovent Biologics Says PD-1 Inhibitor Tyvyt Successfully Included In Updated NDRL

Dec 3 (Reuters) - Innovent Biologics Inc <1801.HK>::PD-1 INHIBITOR TYVYT (SINTILIMAB INJECTION) SUCCESSFULLY INCLUDED IN UPDATED NATIONAL REIMBURSEMENT DRUG LIST.Further company coverage: 1801.HK. ((Reuters.Briefs@thomsonreuters.com;)).

Adage Capital Partners Raises Stake in Tesla, Merck, Takes In Moderna, Novavax

Nov 15 (Reuters) - Adage Capital Partners: :ADAGE CAPITAL PARTNERS TAKES SHARES STAKE OF 327,128 SHARES IN MODERNA INC - SEC FILING.ADAGE CAPITAL PARTNERS TAKES SHARES STAKE OF 10,000 SHARES IN NOVAVAX - SEC FILING.ADAGE CAPITAL PARTNERS RAISES SHARE STAKE IN TESLA INC BY 6.7% TO 679,500 SHARES - SEC FILING.ADAGE CAPITAL PARTNERS RAISES SHARE STAKE IN MERCK & CO INC BY 19.7% TO 1.8 MILLION SHARES - SEC FILING.ADAGE CAPITAL PARTNERS RAISES SHARE STAKE IN ELI LILLY BY 45.1% TO 1.2 MILLION SHARES - SEC FILING.ADAGE CAPITAL PARTNERS RAISES SHARE STAKE IN MATCH GROUP FROM 50,000 SHARES TO 296,696 SHARES - SEC FILING.ADAGE CAPITAL PARTNERS RAISES SHARE STAKE IN GOLDMAN SACHS BY 47.7% TO 293,600 SHARES - SEC FILING.ADAGE CAPITAL PARTNERS RAISES SHARE STAKE IN NVIDIA CORPORATION TO 2.6 MILLION SHARES FROM 654,981 SHARES - SEC FILING.ADAGE CAPITAL PARTNERS GP LLC - CHANGE IN HOLDINGS ARE AS OF SEPTEMBER 30, 2021 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF JUNE 30, 2021.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up